share_log

康希諾生物：自願公告 - 關於吸附破傷風疫苗啟動III期臨床試驗並完成首例受試者入組的公告

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR ABSORBED TETANUS VACCINE

香港交易所 ·  Mar 20 05:25
Summary by Moomoo AI
康希諾生物股份公司（「本公司」）於2024年3月20日宣布，公司自主研發的吸附破傷風疫苗已正式啟動III期臨床試驗並完成首例受試者入組。此次臨床試驗旨在評估該疫苗在18歲及以上人群中接種後的安全性和免疫原性。本公司表示，該疫苗採用無動物源培養基進行發酵，具有更高的安全性，並已確定產業化規模工藝，工藝穩定。該疫苗主要用於預防非新生兒破傷風，預期將豐富公司產品線並提升核心競爭力。公司股東及潛在投資者應審慎行事。公告中提及的董事會成員包括執行董事Xuefeng YU博士、Shou Bai CHAO博士及王靖女士；非執行董事梁頴宇女士；以及獨立非執行董事桂水發先生、劉建忠先生及張耀樑先生。
康希諾生物股份公司（「本公司」）於2024年3月20日宣布，公司自主研發的吸附破傷風疫苗已正式啟動III期臨床試驗並完成首例受試者入組。此次臨床試驗旨在評估該疫苗在18歲及以上人群中接種後的安全性和免疫原性。本公司表示，該疫苗採用無動物源培養基進行發酵，具有更高的安全性，並已確定產業化規模工藝，工藝穩定。該疫苗主要用於預防非新生兒破傷風，預期將豐富公司產品線並提升核心競爭力。公司股東及潛在投資者應審慎行事。公告中提及的董事會成員包括執行董事Xuefeng YU博士、Shou Bai CHAO博士及王靖女士；非執行董事梁頴宇女士；以及獨立非執行董事桂水發先生、劉建忠先生及張耀樑先生。
Consino Biologics Corporation (the “Company”) announced on March 20, 2024 that the Company's independently developed aspirated pneumothorax vaccine has officially commenced Phase III clinical trials and completed the initial cohort of test subjects. This clinical trial aims to assess the safety and immunogenicity of the vaccine in people aged 18 and over. The company said that the vaccine is fermented using animal-based culture without animal sources, has higher safety and has been determined to be industrialized and process stable. The vaccine is primarily used to prevent non-neonatal stroke and is expected to enrich the company's product line and enhance core competitiveness. Shareholders and potential investors should act with caution. The Board members mentioned in the announcement include Executive Directors Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Wang Jing; Ms. Leung Wing Yu, Non-Executive Director; and Independent Non-Executive Directors Mr. Kwai Shuifa, Mr. Liu Jianchong and Mr. Zhang Yiu Leung.
Consino Biologics Corporation (the “Company”) announced on March 20, 2024 that the Company's independently developed aspirated pneumothorax vaccine has officially commenced Phase III clinical trials and completed the initial cohort of test subjects. This clinical trial aims to assess the safety and immunogenicity of the vaccine in people aged 18 and over. The company said that the vaccine is fermented using animal-based culture without animal sources, has higher safety and has been determined to be industrialized and process stable. The vaccine is primarily used to prevent non-neonatal stroke and is expected to enrich the company's product line and enhance core competitiveness. Shareholders and potential investors should act with caution. The Board members mentioned in the announcement include Executive Directors Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Wang Jing; Ms. Leung Wing Yu, Non-Executive Director; and Independent Non-Executive Directors Mr. Kwai Shuifa, Mr. Liu Jianchong and Mr. Zhang Yiu Leung.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more